CCNE2 and neoplasm: Initial triple combination of endocrine therapy, CDK4/6i and PI3Ki in vitro and in patient-derived xenografts achieved greater cell cycle arrest, decreased cyclin E2 and CDK2 expression with subsequent induction of apoptosis, and induced greater tumor regression than each inhibitor alone22.